tiprankstipranks
Trending News
More News >
Sight Sciences, Inc. (SGHT)
:SGHT
US Market
Advertisement

Sight Sciences (SGHT) AI Stock Analysis

Compare
82 Followers

Top Page

SGHT

Sight Sciences

(NASDAQ:SGHT)

Rating:45Neutral
Price Target:
$3.50
▼(-7.41%Downside)
The overall stock score is primarily influenced by financial performance challenges, including declining revenues, persistent net losses, and negative free cash flow. Technical analysis indicates neutral momentum, while valuation is impacted by negative earnings. Despite some positives, such as a strong gross margin and liquidity position, the stock faces significant operational and market challenges.
Positive Factors
Financial Stability
Sight maintains a solid $120 million cash position, enabling flexibility for ongoing product launches, market access efforts, and further R&D investments.
Product Performance
TearCare is preferred for its superior patient comfort and long-lasting benefits, indicating high patient satisfaction and clinical effectiveness.
Revenue Performance
SGHT's first-quarter sales of $17.5 million were $1 million above estimates, showcasing better-than-expected performance.
Negative Factors
Market Access
While market access remains a challenge, TearCare's potential to disrupt the dry eye market is contingent on receiving reimbursement coverage.
Sales Guidance
Management reiterated full-year sales guidance of a 6% to 12% decline year-over-year, indicating ongoing challenges.
Tariffs Impact
Tariffs are expected to be a ~$4M headwind, with management beginning to transition manufacturing outside of China.

Sight Sciences (SGHT) vs. SPDR S&P 500 ETF (SPY)

Sight Sciences Business Overview & Revenue Model

Company DescriptionSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
How the Company Makes MoneySight Sciences generates revenue through the sale of its medical devices and products that target eye diseases. The company's key revenue streams include the sales of its proprietary technologies, such as the OMNI Surgical System for glaucoma treatment and the TearCare System for dry eye disease management. These products are sold to eye care professionals and healthcare facilities. Sight Sciences also benefits from strategic partnerships and collaborations within the medical community, which help in broadening its market reach and enhancing product adoption. The company's earnings are primarily driven by the expansion of its customer base and the increasing demand for effective eye disease treatments.

Sight Sciences Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 24.75%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with solid performance in the surgical glaucoma segment and positive reception of new product launches, but faced challenges with revenue declines, tariff costs, and the lack of reimbursement for TearCare. The company's strategic initiatives and cost management are showing progress, yet external market conditions and reimbursement hurdles remain significant concerns.
Q1-2025 Updates
Positive Updates
Solid First Quarter Revenue
Sight Sciences reported a total revenue of $17.5 million for the first quarter of 2025, reflecting the significance of their interventional technologies despite a dynamic MIGS market.
Stable Surgical Glaucoma Revenue
Surgical glaucoma revenue for Q1 2025 was $17.1 million, with only a slight decline in sequential ordering accounts despite Medicare coverage restrictions, indicating resilience in the market.
Next-Generation OmniEdge Launch
The company launched OmniEdge, a new addition to their MIGS platform, receiving positive early reception from surgeons for its advanced technology.
Strong Gross Margins
Gross margin for the first quarter was 86%, remaining flat compared to the same period in the prior year, indicating stable cost management.
Reduced Net Loss
Net loss for the first quarter was $14.2 million, or $0.28 per share, compared to a net loss of $16.3 million, or $0.33 per share, for the first quarter of 2024, showing improved financial management.
Negative Updates
Overall Revenue Decline
Total revenue decreased by 9% compared to the same period in the prior year, primarily due to the impact of the new Medicare coverage restrictions on the MIGS market.
Dry Eye Segment Revenue Drop
Dry eye revenue for the first quarter of 2025 was $400,000, a significant decrease from $1 million in the same period in the prior year, mainly due to fewer SmartLids sales.
Tariff Cost Challenges
Material tariff increases on goods imported from China are expected to impact cost of goods sold, increasing costs by $3.5 million to $4.5 million for full year 2025.
No Reimbursement for TearCare Yet
TearCare has not yet received any reimbursement coverage decisions, which is crucial for driving growth in the dry eye segment.
Company Guidance
In the first quarter of 2025 earnings call, Sight Sciences provided guidance for the full year, reaffirming its revenue expectations of approximately $70 million to $75 million and adjusting its operating expense guidance to a range of $101 million to $105 million, reflecting a focus on cost controls to offset tariff impacts on goods imported from China. The company reported total revenue of $17.5 million for the first quarter, with surgical glaucoma revenue accounting for $17.1 million and dry eye revenue at $400,000. Despite a 9% year-over-year decrease in total revenue attributed to new Medicare coverage restrictions on multiple MIGS procedures, Sight Sciences emphasized its long-term strategic initiatives, including advancing its product pipeline, expanding manufacturing outside China, and pursuing reimbursement decisions for its TearCare technology. The company's gross margin remained stable at 86%, while operating expenses decreased by 7%, contributing to a net loss of $14.2 million for the quarter.

Sight Sciences Financial Statement Overview

Summary
Sight Sciences faces challenges with declining revenues and consistent net losses, despite strong gross margins and liquidity with no debt. The persistent negative cash flow and declining equity suggest potential sustainability concerns.
Income Statement
40
Negative
Sight Sciences shows a declining revenue trend with a revenue decrease from $81.1M in 2023 to $79.9M in 2024, marking a negative revenue growth rate of -1.47%. The company is also operating at a loss, with a net profit margin of -64.5% in 2024, which is a slight improvement from -68.5% in 2023. The gross profit margin is relatively high at 85.5% in 2024, indicating efficient cost management concerning direct costs, but there is a consistent negative EBIT and EBITDA margin due to high operating expenses.
Balance Sheet
55
Neutral
The balance sheet reflects a strong liquidity position with a significant amount of cash and cash equivalents ($120.4M) and no debt as of 2024, resulting in a net negative debt position. The equity ratio stands at 61.3%, indicating a solid equity foundation. However, the company has been experiencing a decrease in stockholders' equity from $120.2M in 2023 to $87.5M in 2024. The absence of debt reduces financial risk, but declining equity could be a concern.
Cash Flow
35
Negative
Free cash flow remains negative at -$22.7M in 2024, though there is an improvement from -$47.9M in 2023. The operating cash flow to net income ratio is close to 0.43, reflecting some alignment between operational cash generation and reported losses. Despite improvement, persistent negative cash flows highlight ongoing challenges in generating sufficient cash from operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue79.87M81.06M71.33M48.96M27.64M
Gross Profit68.28M69.17M58.97M40.35M18.43M
EBITDA-45.90M-49.41M-80.48M-57.20M-31.68M
Net Income-51.51M-55.55M-86.24M-62.96M-34.69M
Balance Sheet
Total Assets142.84M166.65M213.07M280.19M72.81M
Cash, Cash Equivalents and Short-Term Investments120.36M138.13M185.00M260.69M61.51M
Total Debt40.36M35.41M34.35M32.66M32.48M
Total Liabilities55.32M46.44M53.00M48.08M161.66M
Stockholders Equity87.52M120.22M160.08M232.11M-88.85M
Cash Flow
Free Cash Flow-22.74M-47.98M-76.94M-53.35M-33.13M
Operating Cash Flow-22.35M-47.18M-75.97M-52.54M-32.17M
Investing Cash Flow-385.00K-791.00K-970.00K-813.00K-953.00K
Financing Cash Flow4.96M1.10M1.25M252.53M73.40M

Sight Sciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.78
Price Trends
50DMA
3.78
Positive
100DMA
3.24
Positive
200DMA
3.57
Positive
Market Momentum
MACD
-0.09
Positive
RSI
51.90
Neutral
STOCH
59.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGHT, the sentiment is Positive. The current price of 3.78 is above the 20-day moving average (MA) of 3.75, above the 50-day MA of 3.78, and above the 200-day MA of 3.57, indicating a bullish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 51.90 is Neutral, neither overbought nor oversold. The STOCH value of 59.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGHT.

Sight Sciences Risk Analysis

Sight Sciences disclosed 53 risk factors in its most recent earnings report. Sight Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sight Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$224.22M-76.01%25.62%11.86%
54
Neutral
$5.39B-20.36%23.92%19.82%
50
Neutral
$178.49M271.41%85.03%53.73%
47
Neutral
$156.67M-304.05%28.24%-334.39%
46
Neutral
C$200.02M-3.36-23.14%1.86%20.75%-0.36%
45
Neutral
$184.06M-52.87%-4.16%12.79%
45
Neutral
$321.03M-11.98%46.69%46.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SGHT
Sight Sciences
3.56
-4.19
-54.06%
GKOS
Glaukos
96.00
-23.82
-19.88%
LNSR
LENSAR
12.93
7.49
137.68%
TLSI
TriSalus Life Sciences
4.67
-1.03
-18.07%
CVRX
CVRx
8.19
-1.42
-14.78%
RXST
RxSight
7.94
-36.56
-82.16%

Sight Sciences Corporate Events

Executive/Board ChangesShareholder Meetings
Sight Sciences Holds Annual Stockholders Meeting
Neutral
Jun 5, 2025

On April 21, 2025, Sight Sciences, Inc. appointed Gerhard F. Burbach to its Board of Directors and the Audit Committee. At the annual stockholders meeting on June 5, 2025, the company elected three Class I directors and ratified Deloitte & Touche LLP as its independent accounting firm for the fiscal year ending December 31, 2025. The meeting saw participation from approximately 75.1% of the company’s outstanding shares.

The most recent analyst rating on (SGHT) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Sight Sciences Reports Q1 2025 Financial Results
Negative
May 8, 2025

On May 8, 2025, Sight Sciences reported its financial results for the first quarter of 2025, showing a 9% decrease in total revenue compared to the previous year, primarily due to reduced revenue from its Surgical Glaucoma segment. The company reaffirmed its full-year revenue guidance for 2025, despite challenges posed by new Medicare LCDs affecting the MIGS market and tariff impacts on its products manufactured in China. Sight Sciences also launched OMNI Edge, a new product in its surgical system line, and announced improved adjusted operating expenses guidance for the year.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025